SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-18-024362
Filing Date
2018-10-17
Accepted
2018-10-17 06:59:56
Documents
7
Period of Report
2018-10-17
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K agle-8k_20181017.htm 8-K 35186
2 EX-99.1 agle-ex991_6.htm EX-99.1 20998
3 EX-99.2 agle-ex992_7.htm EX-99.2 1158
4 EX-99.3 agle-ex993_37.htm EX-99.3 1160
5 GRAPHIC gzxdwavvndk1000001.jpg GRAPHIC 178264
6 GRAPHIC gbmggug5ogok000001.jpg GRAPHIC 3061
7 GRAPHIC gsyvek5gmurv000001.jpg GRAPHIC 196878
  Complete submission text file 0001564590-18-024362.txt   581014
Mailing Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746
Business Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 181125393
SIC: 2834 Pharmaceutical Preparations